title: Imatinib (Gleevec)-induced hepatotoxicity.
abstract: Imatinib (Gleevec, Novartis Pharmaceuticals Corp, East Hanover, NJ) is widely used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors. To our knowledge, only one case report of histologically proven Imatinib-induced hepatotoxicity has been reported. We describe another case of hepatotoxicity in a 22-year-old woman including the histopathologic changes and the clinical course after the discontinuation of Imatinib.
authors.affiliation: Center for Liver and Kidney Diseases and Transplantation, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA.
authors.forename: Walid S
authors.initials: WS
authors.lastname: Ayoub
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Geller
authors.forename: Tram
authors.initials: T
authors.lastname: Tran
authors.forename: Paul
authors.initials: P
authors.lastname: Martin
authors.forename: John M
authors.initials: JM
authors.lastname: Vierling
authors.forename: F Fred
authors.initials: FF
authors.lastname: Poordad
mesh_terms: D000328:Adult; D001549:Benzamides; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D010879:Piperazines / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000009:adverse effects*
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases